Asset
SUVODIRSEN
Wave Life Sciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03907072 | phase2_3 | terminated | 2019-09-04 | 2019-12-16 | Wave Life Sciences USA, Inc. | Efficacy and Safety Study of WVE-210201 (Suvodirsen) With Open-label Extension in Ambulatory Patients With Duchenne Muscular Dystrophy |
| NCT03508947 | phase1 | completed | 2018-01-24 | 2019-03-06 | Wave Life Sciences USA, Inc. | Safety and Tolerability of WVE-210201 in Patients With Duchenne Muscular Dystrophy |
FDA applications (0)
This company has no applications containing this asset.